Genoa Pharmaceuticals, Inc., a Seattle, WA-based biopharmaceutical company, completed a $62m Series A round of financing.
The round was led by F-Prime Capital Partners and Edmond de Rothschild Investment Partners with participation from Novo AS, RiverVest Venture Partners, and TPG Biotech. In conjunction with the funding, venture capitalists Ketan Patel, M.D., Naveed Siddiqi M.D., Tiba Aynechi Ph.D., Niall O’Donnell, Ph.D., and Heather Preston, M.D. joined the board of directors. Jonathan Leff, M.D, former Executive Vice President of Research and Development at InterMune and who led the oral pirfenidone (Esbriet®) approval process, was appointed an independent director.
The company intends to use the funds to advance its early-stage pipeline and test Aerodone™ for the treatment of IPF through Phase 2 clinical trials.
Led by A. Bruce Montgomery, M.D., CEO, and Mark Surber, Ph.D., founder and chief scientific officer, Genoa Pharmaceuticals is a biopharmaceutical company committed to developing improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe pulmonary diseases. Its lead program (Aerodone™; inhaled pirfenidone) is on track to enter clinical development by year’s end. Aerodone™ for the treatment of IPF has been granted orphan-drug designation by the US FDA.